Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-2 day-1 as a continuous infusion for 4 days combined with interferon alpha (IFN-alpha) 6 MIU m-2 day-1 subcutaneously on days 1 and 4. The cycle was repeated every 2 weeks for a maximum number of 13 cycles. Of the 51 evaluable patients, one (2%) achieved a complete and seven (14%) a partial response (total response rate 16%; CI 7-29%). Median time to progression and median survival were 2.5 and 11.3 months respectively. This regimen of IL-2 and IFN-alpha appeared to be only moderately active.
Kruit
W H
WH
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
Goey
S H
SH
Calabresi
F
F
Lindemann
A
A
Stahel
R A
RA
Poliwoda
H
H
Osterwalder
B
B
Stoter
G
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use* / Q000633:toxicity; D007376:Interleukin-2 / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins / Q000627:therapeutic use / Q000633:toxicity; D015996:Survival Rate; D013997:Time Factors
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins